Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23993928 | 1.00 | KDM1A (0.40) | KDM1ARCOR1SLC6A4MAOBCCR6 | |
| SCHEMBL23994512 | 1.00 | KDM1A (0.40) | KDM1ARCOR1SLC6A4MAOBCCR6 | |
| SCHEMBL30181555 | 1.00 | KDM1A (0.40) | KDM1ARCOR1SLC6A4MAOBCCR6 | |
| SCHEMBL30224756 | 0.85 | FFAR1 (0.38) | KDM1AEPHX2LIPE | |
| SCHEMBL25005864 | 0.83 | MMP13 (0.34) | LIPE | |
| SCHEMBL30181625 | 0.83 | MMP13 (0.34) | LIPE | |
| SCHEMBL25005863 | 0.83 | MMP13 (0.34) | LIPE | |
| SCHEMBL23994266 | 0.83 | MMP13 (0.34) | LIPE | |
| SCHEMBL3745573 | 0.82 | KDM1A (0.49) | KDM1ASLC6A4MAOBSLC6A3SLC6A2 | |
| SCHEMBL30181639 | 0.82 | LIPE (0.34) | SLC6A4LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | KDM1A 2052/4885RCOR1 4471/4885SLC6A4 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.